Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00408681 · OUTCOME

Causes of Death

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant · Source last updated 2017-03-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
up to 6 years after enrollment

What was measured

Medical condition that made the greatest contribution in causing death

Groups in this outcome

Treated Patients

Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treated Patients20

Reported measurements

Recurrent or progressive malignancy
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients2Not reportedNot reportedNot reportedNot reported
Acute graft-versus-host disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients11Not reportedNot reportedNot reportedNot reported
Chronic GVHD with bronchiolitis obliterans
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients2Not reportedNot reportedNot reportedNot reported
Infection
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients7Not reportedNot reportedNot reportedNot reported
Multiorgan failure
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients2Not reportedNot reportedNot reportedNot reported
Diffuse alveolar hemorrhage
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients1Not reportedNot reportedNot reportedNot reported
Hemolytic uremic syndrome
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Recurrent or progressive malignancy
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        11
    title
    Acute graft-versus-host disease
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Chronic GVHD with bronchiolitis obliterans
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        7
    title
    Infection
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Multiorgan failure
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Diffuse alveolar hemorrhage
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Hemolytic uremic syndrome
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Medical condition that made the greatest contribution in causing death
groups
  1. description
    Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treated Patients
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
up to 6 years after enrollment
title
Causes of Death
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice